Clinical trial Apple
APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | EORTC |
| EudraCT Identifier | 2016-001834-82 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02856893 |
| Inclusion criteria | EGFR activating mutation associated with EGFR-TKI sensitivity |
| Last update |